TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data Huy Gia Vuong, Ahmed M.A. Altibi, Uyen N.P. Duong, Hanh T.T. Ngo, Thong Quang Pham, Aden Ka-Yin Chan, Chul-Kee Park, Kar- Ming Fung, Lewis Hassell Critical Reviews in Oncology / Hematology Volume 120, Pages 1-9 (December 2017) DOI: 10.1016/j.critrevonc.2017.09.013 Copyright © 2017 Elsevier B.V. Terms and Conditions
Fig. 1 Flowchart of the study. Abbreviations: WoS, Web of Science; VHL, Virtual Health Library. Critical Reviews in Oncology / Hematology 2017 120, 1-9DOI: (10.1016/j.critrevonc.2017.09.013) Copyright © 2017 Elsevier B.V. Terms and Conditions
Fig. 2 Prognostic impact of TERT promoter mutations on overall survival (A) and progression-free survival (B) of gliomas. Critical Reviews in Oncology / Hematology 2017 120, 1-9DOI: (10.1016/j.critrevonc.2017.09.013) Copyright © 2017 Elsevier B.V. Terms and Conditions
Fig. 3 Prognostic impact of TERT promoter mutations on overall survival of IDH-wild type (A) and IDH-mutated WHO grade II/III gliomas. Critical Reviews in Oncology / Hematology 2017 120, 1-9DOI: (10.1016/j.critrevonc.2017.09.013) Copyright © 2017 Elsevier B.V. Terms and Conditions
Fig. 4 Aggregate data of median OS (months) of WHO grade II/III gliomas in the included studies. Critical Reviews in Oncology / Hematology 2017 120, 1-9DOI: (10.1016/j.critrevonc.2017.09.013) Copyright © 2017 Elsevier B.V. Terms and Conditions